Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: The LIFE study

Journal of Human Hypertension

Volumn 18, Issue 6, 2004, Pages 411-416

  Bella, Jonathan N ^a,i   Palmieri, V ^a   Wachtell, K ^b   Liu, J E ^a   Gerdts, E ^c   Nieminen, M S ^d   Koren, M J ^e   Zabalgoitia, M ^f   Wright, J T ^g   Dahlof B ^h   Devereux, R B ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e Clinic Jacksonville   (United States)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^g UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^h SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ BRONX LEBANON HOSPITAL CENTER   (United States)

Author keywords

Echocardiography; Hypertension; Hypertrophy; Left ventricle; Sex

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOSARTAN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART OUTPUT; HEART STROKE VOLUME; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; ATENOLOL; FEMALE; FOLLOW-UP STUDIES; HEART VENTRICLES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LOSARTAN; MALE; MIDDLE AGED; REMISSION INDUCTION; SEX FACTORS; TIME FACTORS;

EID: 2942756021     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001708     Document Type: Article

References (37)

1. Casale PN et al. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986; 105: 173-178.
2. Koren MJ et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 345-352.
3. Liao Y et al. The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA 1995; 273: 1592-1597.
4. Levy D et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.
5. de Simone G, Devereux RB, Daniels SR, Meyer RA. Gender differences in left ventricular growth. Hypertension 1995; 26: 979-983.
6. Krumholz HM, Larson M, Levy D. Sex differences in cardiac adaptation to isolated systolic hypertension. Am J Cardiol 1993; 72: 310-313.
7. Carroll JD et al. Sex-associated differences in left ventricular function in aortic stenosis of the elderly. Circulation 1992; 86: 1099-1107.
8. Douglas PS et al. Gender differences in left ventricle geometry and function in patients undergoing balloon dilatation of the aortic valve for isolated aortic stenosis. NHLBI Balloon Valvuloplasty Registry. Br Heart J 1995; 73: 548-554.
9. Gerdts E et al. Gender differences in systolic left ventricular function in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study). Am J Cardiol 2001; 87: 980-983.
10. Liebson PR et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1995; 91: 698-706.
11. Gottdiener JS et al. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation 1997; 95: 2007-2014.
12. Devereux RB et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial. Circulation 2001; 104: 1248-1254.
13. Dahlof B et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE study group. Am J Hypertens 1997; 10: 705-713.
14. Dahlöf B et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
15. Wachtell K et al. Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population: the LIFE study. Hypertension 2000; 35: 6-12.
16. Devereux RB, Roman MJ. Evaluation of cardiac function and vascular structure and function by echocardiography and other noninvasive techniques. In: Laragh JH, Brenner BM, (eds). Hypertension: Pathophysiology, Diagnosis, and Management. Raven Press Ltd: New York, 1995, pp 1969-1985.
17. Devereux RB, Dahlof B, Levy D, Pfeffer MA. Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial). Am J Cardiol 1996; 78: 61-65.
18. Devereux RB et al, Relations of left ventricular mass to demographic and hemodynamic variables in American Indians: the Strong Heart Study. Circulation 1997; 96: 1416-1423.
19. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083.
20. Schiller NB et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2: 358-367.
21. Devereux RB et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450-458.
22. Palmieri V et al. Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement. J Am Coll Cardiol 1999; 34: 1625-1632.
23. Reichek N, Devereux RB. Reliable estimation of peak left ventricular systolic pressure by M-mode echographic-determined end-diastolic relative wall thickness: identification of severe valvular aortic stenosis in adult patients. Am Heart J 1982; 103: 202-203.
24. Dubin J, Wallerson DC, Cody RJ, Devereux RB. Comparative accuracy of Doppler echocardiographic methods for clinical stroke volume determination. Am Heart J 1990; 120: 116-123.
25. Fagard RH, Pardaens K, Staessen JA, Thijs L. The pulse pressure-to-stroke index ratio predicts cardiovascular events and death in uncomplicated hypertension. J Am Coll Cardiol 2001; 38: 227-231.
26. Devereux RB et al. Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. Blood Press 2001; 10: 74-82.
27. Gardin JM et al. Left ventricular diastolic filling in the elderly: the cardiovascular health study. Am J Cardiol 1998; 82: 345-351.
28. Bella JN et al. Gender difference in diastolic function in hypertension (the HyperGEN study). Am J Cardiol 2002; 89: 1052-1056.
29. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996; 275: 1507-1513.
30. Municino A, Palmieri V, Dahlof B, De Quattro V et al. Impact of anti-hypertensive treatment on left ventricular geometric patterns: The PRESERVE study. Am J Hypertens 2000; 14(Part 2): 52A.
31. Capasso JM, Remily RM, Smith RH, Sonnenblick EH. Sex differences in myocardial contractility in the rat. Basic Res Cardiol 1983; 78: 156-171.
32. Scheuer J, Malhotra A, Schaible TF, Capasso J. Effects of gonadectomy and hormonal replacement on rat hearts. Circ Res 1987; 61: 12-19.
33. Grohe C et al. Cardiac myocytes and fibroblasts contain functional estrogen receptors. FEBS Lett 1997; 416: 107-112.
34. Villari B et al. Sex-dependent differences in left ventricular function and structure in chronic pressure overload. Eur Heart J 1995; 16: 1410-1419.
35. Querejeta R et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 2000; 101: 1729-1735.
36. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000; 102: 1388-1393.
37. Lopez B et al. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001; 104: 286-291.